What is GeneDx Holdings's impairment charges?

GeneDx Holdings (WGS) reported impairment charges of $31.29M in Q1 2026.

What does impairment charges mean?

Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.

GeneDx Holdings WGS Impairment Charges

Impairment Charges at other companies

RevvityRVTY

$1.2M-79.0%

Agilent TechnologiesA

$15M—

AzentaAZTA

$149.08M—

Charles River LaboratoriesCRL

$15.86M+50.0%

Guardant HealthGH

$0-100%

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.89B-24.3%

Enterprise value$1.89B-22.8%

P/S4.3×-3.3×

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's impairment charges?: GeneDx Holdings (WGS) reported impairment charges of $31.29M in Q1 2026.
What does impairment charges mean?: Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.